EB142: KEI statement on WHO’s decision on the Global strategy and plan of action on public health, innovation and intellectual property

After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading

Comparison between April 29, May 7, and May 10 versions of WHA 72 resolution on transparency

On Monday, May 13th, Politico published the latest version (May 10, 2019) of the transparency resolution noting the “dizzying number of brackets” in the latest text. The original sponsors are: Italy, Greece, Malaysia, Portugal, Serbia, Slovenia, South Africa, Spain, Turkey,… Continue Reading

WHO donors in 2018 – US, Gates Foundation, UK, GAVI, Germany, OCHA, and Japan: Setting the Agenda for Global Health?

In advance of the 72nd World Health Assembly (20 May 2019 – 28 May 2019), the World Health Organization (WHO) published a document (A72/INF./5, 9 May 2019) entitled, Voluntary contributions by fund and by contributor, 2018. Total voluntary contributions to… Continue Reading

WTO TRIPS Council: South Africa considers strict patentability criteria to address abuses in the pharmaceutical industry

On 1 February 2019, the World Trade Organization (WTO) published a submission (IP/C/W/651) by South Africa to the TRIPS Council on Intellectual Property and the Public Interest: Promoting Public Health Through Competition Law and Policy. The South African paper endeavors… Continue Reading

Pfizer’s efforts to block Colombia’s accession to the OECD in 2017-2018

The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading